November 2013

Indonesia: Market Access Tracker - 2013

Report Authors
Jonathan Chan, M.MedSc.
Neil Grubert, M.A.
Michael Latwis, M.B.A.
Gilan Megeed, M.P.H.
Nikhil Mehta, M.Eng.
Andreia Ribeiro, Ph.D.
Michael Yeung, M.Sc.


Last Updated 14 November 2013
Continued growth of Indonesia’s economy and pharmaceutical market offers revenue-generating opportunities for multinational companies, but it is clear that successful entry or expansion in this emerging market will depend on understanding the country’s rapidly evolving healthcare reforms, regulatory requirements, and political realities. Increasing national investment in the country’s healthcare and a government commitment to provide universal healthcare coverage by 2019 will boost demand for healthcare services over the next five years. Reforms should ultimately provide greater access to medicines for more Indonesians. However, the government intends to meet the predicted rise in drug consumption with generic drugs and has implemented various policies favoring the domestic pharmaceutical industry. Branded drug developers must also prepare for a new reality of price controls and health technology assessments.


Market profile: Market access drivers; key opportunities and challenges; analysis of more than 40 market parameters.

Economic outlook: Global, regional, and country growth rates, 2011-2014.

Socioeconomic trends of 11 Asia-Pacific countries: Gross domestic product (GDP); nominal per capita gross national income (GNI).

Demographics of 11 Asia-Pacific countries projected to 2030: Population size; population growth rate; life expectancy at birth; median age; percentage of population aged 65 or more; percentage of population that is urban; tier I and tier II markets based on population; morbidity and mortality.

Healthcare investments of 11 Asia-Pacific countries: Healthcare spending as percentage of GDP (2000-2010); healthcare spending by government and private entities (2010); healthcare spending per capita (2000-2010).

Pharmaceutical markets (3 regions and 15 countries): Ranking by size; market sizes; market growth.

Healthcare system: Organization and financing of public and private sectors; healthcare providers and facilities; health insurance schemes; healthcare reform plans; national health insurance.

Regulatory affairs: Key decision makers; laws, regulations, and guidelines; ASEAN regulatory harmonization; local manufacturing requirements; clinical trials in Indonesia; registration process; Bolar-type amendment for generics registration.

Pricing and reimbursement: Key decision makers; public sector tender and procurement; pricing; admission to drug lists and formularies; health technology assessment.

Cost-containment measures: Generic substitution; government strategies to promote unbranded generics; generic price-capping; rational drug use.

Intellectual property protection: Key decision makers; patent protection; data exclusivity; patent linkage; compulsory licensing; government-use licensing; counterfeit drugs.

Outlook and implications for the pharmaceutical industry: Key factors to appreciate when doing business in Indonesia.

Exhibits: 20 data-rich tables and figures.

Fill out the form below to contact sales.

Search Reports

Mentioned in this report:

  • Organizations
  • - Association of Southeast Asia Nations (ASEAN)
  • - Badan Penyelenggara Jaminan Sosial (BPJS; National Social Security Agency)
  • - Directorate General of Intellectual Property Rights (DGIPR)
  • - Directorate General of Pharmaceuticals and Medical Devices (DGPMD)
  • - International Conference on Harmonization (ICH)
  • - International Monetary Fund (IMF)
  • - Komite Nasional Penilai Obat Jadi (KOMNAS POJ; National Committee on Drug Evaluation)
  • - National Agency of Drug and Food Control (NADFC)
  • - National Indonesian Technical Advisory Group (NITAG)
  • - National Institute for Health and Care Excellence (NICE)
  • - Trade-Related Aspects of Intellectual Property Rights (TRIPS)
  • - United Nations Population Division (NHPD)
  • - World Bank
  • - World Trade Organization (WTO)
Decision Resources Group brands include: